Late-breaking poster presentations (as of 9/20/23)

Poster Session C
Saturday, October 14 | 12:30 pm-4:00 pm
Level 2, Exhibit Hall D

LB_C02: *A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients (pts) with cachexia and elevated GDF-15 levels*. Martin Birkhofer, AVEO Oncology, Boston, MA United States.

LB_C03: *Protein translation inhibition enforces histone deacetylase inhibitor activity resulting in synergistic pancreatic cancer cell death*. Maryam Safari, Columbia University Medical Center, New York, NY United States.

LB_C04: *Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models*. Mariana Paes Dias, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

LB_C05: *A novel approach to convert non-resectable pancreatic cancer with major artery involvement using endovascular activation of Padeliporfin by vascular-targeted photodynamic therapy*. Dina Preise, Impact Biotech Ltd, The Weizmann Institute of Science, Ness Siona, Rehovot, Israel.

LB_C06: *Utilizing a novel HDAC inhibitor bocodepsin (OKI-179) to overcome doxorubicin resistance in triple-negative breast cancer*. Stephen G. Smoots, CU Anschutz, Denver, CO United States.

LB_C07: *Utilizing a BCL-2 inhibitor (venetoclax) to overcome doxorubicin resistance in triple-negative breast cancer*. Evan Dus, University of Colorado Anschutz, Aurora, CO United States.

LB_C09: *QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity.* Jillian M. Silva, Quanta Therapeutics, South San Francisco, CA United States.

LB_C10: *An orally available small molecule inhibitor for synthetic lethal targeting of MYC expressing tumors*. Thaddeus D. Allen, Anticancer Bioscience, Inc., San Francisco, CA United States.

LB_C11: *Small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes*. Sarah Truong, Rakovina Therapeutics, Vancouver, BC Canada.

LB_C12: *Alisertib and pembrolizumab in Rb-deficient head and neck squamous cell carcinomas (HNSCC)*. Faye M. Johnson, University of Texas MD Anderson Cancer Center, Houston, TX United States.

LB_C13: *Development of BLX-3030, a Potent, Selective, Orally Available CDK9i shows promise in Pancreatic Ductal Adenocarcinoma (PDAC) Models*. Kyle Medley, Biolexis Therapeutics, Inc., American Fork, UT United States.

LB_C14: *EAI-432: A mutant-selective allosteric EGFR inhibitor for L858R-mutant non-small cell lung cancer*. Michael J. Eck, Dana-Farber Cancer Institute, Boston, MA United States.

LB_C15: *PI3Kδ/γ inhibitor as a novel immune-regulatory radiosensitizer*. Jae-Sung Kim, Korea Institute of Radiological & Medical Sciences, Nowon-gu, Korea, Republic of.

LB_C16: *Long-read sequencing reveals alternative splicing driven, shared immunogenic neoepitopes regardless SF3B1 status in uveal melanoma*. Jianfeng Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Mainland).

LB_C17: *Spatial Tumor Immune Microenvironment Analysis of KRAS-mutated Non-Small Cell Lung Cancer and Immunotherapy Outcome*. Dan Zhao, MD Anderson Cancer Center, Houson, TX United States.

LB_C18: *A novel WNT-RIP1 signaling pathway promotes colorectal cancer metastasis via induction of EMT*. Jong Kuk Park, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of.

LB_C19: *Suppression of the antitumoral activity of natural killer cells by cancer-associated fibroblasts in a pancreatic TIME-on-Chip model*. Hyo-Jeong Kuh, The Catholic University of Korea, Seoul, Korea, Republic of.

LB_C20: *A tumor-associated chemokine attracts CCR4-expressing CD4$^+$ cells to foster immune repression and tumor aggressiveness in MYCN-driven neuroblastoma*. Xiaodan Qin, Boston University Chobanian & Avedisian School of Medicine, Boston, MA United States.

LB_C21: *Exogenous N-acetylgalactosamine-4-sulfatase(ARSB)-mediated tumor suppression involves effects on chondroitin 4-sulfate binding with SHP-2 and galectin-3, MAPK signaling, and transcriptional events, including epigenetic regulation of P*. Joanne K. Tobacman, University of Illinois Chicago and Jesse Brown VA Medical Center, Chicago, IL United States.

LB_C22: *Dynamic interactions of disordered N-terminal domain of p53 in cancer*. Chunyu Wang, Rensselaer Polytechnic Institute, Troy, NY United States.